Resolve M Therapeutics exits from stealth
Unique platform designed to engage pro-resolution responses to restore immune homeostasis in inflammatory disorders without broad immuno-suppression.
Cambridge, MA, USA, January 22, 2026 – Resolve M Therapeutics, Inc., the biotech aiming to build the world’s first comprehensive pro-resolution platform for target ID, validation and drug discovery for the treatment of inflammatory diseases, has announced its exit from stealth. Resolve M was created through a strategic collaboration between Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., and General Inception, the global biotech company igniter, and reflects a bold commitment to early-stage biotech innovation.
